WIL:LSEWilmington plc Analysis
Data as of 2026-03-11 - not real-time
£257.49
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Wilmington plc trades at £257.49, comfortably below its 20‑day SMA of £275.12 and the 50‑day SMA of £286.28, confirming a short‑term bearish bias. The RSI of 36.8 hints at mild oversold conditions, while a bearish MACD (-7.88 vs signal -5.52) adds pressure. Despite the technical weakness, the company posted a solid 12% revenue growth and an improving forward EPS of £0.283, compressing the forward P/E to 9.1x. The dividend yield remains attractive at 4.55%, but a payout ratio near 92% and a debt‑to‑equity of 74.6% raise sustainability concerns. Analysts are highly optimistic, assigning a “strong buy” rating with a median price target of £475, yet the DCF fair value of £212.5 suggests the market may be overpaying. Volatility is elevated at 42% over the past month, though beta is ultra‑low (0.13), indicating limited systematic risk. The stock’s liquidity is modest, with average daily volumes far below the 10‑day average, which could amplify price swings on news. Overall, the defensive education & training sector offers stability, but regulatory and debt pressures temper the upside. Investors should weigh the strong dividend against its sustainability and the gap between market price and intrinsic valuation before acting.
In the near term, price action is likely to respect the identified support around £246 and face resistance near £292. Medium‑term prospects improve as earnings momentum builds and the forward valuation appears compelling. Long‑term confidence rests on the company’s defensive positioning and cash‑flow generation, provided it can manage leverage and maintain dividend payouts.
In the near term, price action is likely to respect the identified support around £246 and face resistance near £292. Medium‑term prospects improve as earnings momentum builds and the forward valuation appears compelling. Long‑term confidence rests on the company’s defensive positioning and cash‑flow generation, provided it can manage leverage and maintain dividend payouts.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below all major SMAs indicating bearish momentum
- RSI near oversold levels offering limited upside
- Stable but modest volume suggests liquidity constraints
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward EPS growth compresses forward P/E to ~9x
- Attractive dividend yield despite sustainability concerns
- Analyst consensus strong‑buy with high price targets
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Defensive education & training sector provides resilience
- Diversified geographic exposure across UK, US and Europe
- Low beta reduces systematic risk while cash‑flow remains positive
Key Metrics & Analysis
Financial Health
Revenue Growth12.00%
Profit Margin10.28%
P/E Ratio19.8
ROE10.06%
ROA6.55%
Debt/Equity74.64
P/B Ratio215.5
Op. Cash Flow£18.0M
Free Cash Flow£11.3M
Technical Analysis
TrendBearish
RSI36.8
Support£246.00
Resistance£292.00
MA 20£275.12
MA 50£286.28
MA 200£318.21
MACDBearish
VolumeStable
Fear & Greed Index76.27
Valuation
Fair Value£212.51
Target Price£438.80
Upside/Downside70.41%
GradeOvervalued
TypeBlend
Dividend Yield4.55%
Risk Assessment
Beta0.13
Volatility42.25%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.